Lamprene is a brand-name medication that contains clofazimine as its sole active ingredient. Clofazimine is classified as an antibiotic (specifically a riminophenazine dye) used primarily in the treatment of certain mycobacterial infections. It is supplied as a 50 mg pill and is available in Hong Kong only by prescription from a qualified healthcare professional.
Clofazimine exerts its antibacterial effect through several mechanisms that are jointly responsible for its activity against Mycobacterium leprae and related organisms:
These actions together reduce the bacterial load, allowing the immune system to clear the infection. Clinical benefit is typically seen after several weeks of continuous therapy because clofazimine’s effect builds up slowly.
Lamprene is approved in Hong Kong (and internationally) for the treatment of multibacillary leprosy, a chronic infection caused by Mycobacterium leprae. It is used as part of a multidrug regimen that commonly includes dapsone and rifampicin.
In other jurisdictions, clofazimine is also listed for certain atypical mycobacterial infections (e.g., Mycobacterium avium complex) when standard therapies are ineffective, but such uses are not formally approved in Hong Kong.
Clofazimine has been investigated for several off-label indications, most notably:
Off-label use is not approved by the Hong Kong Department of Health or other regulatory agencies. It requires careful medical supervision and a risk-benefit assessment by a specialist.
These effects are usually reversible after discontinuation, though pigmentation may persist for months.
Exact dosing must be individualized by the prescribing clinician.
This article provides educational information about Lamprene and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Clofazimine can lead to a reddish-brown discoloration of bodily fluids, including urine, especially after prolonged treatment. This change is harmless and resolves after the drug is discontinued.
Skin pigmentation typically lightens gradually over several months to a year after therapy ends, but some residual coloration may persist indefinitely in heavily pigmented areas.
Clofazimine can precipitate hemolysis in individuals with G6PD deficiency, although this is rare. Screening for G6PD deficiency is advisable before initiating therapy in at-risk populations.
A 50 mg Lamprene tablet is imprinted with the code “L-50” on one side and “C” on the opposite side, identifying the brand and strength.
Yes, but keep the medication in its original pharmacy-labelled container, carry a copy of the prescription, and be prepared to declare it at customs if required by the destination country.
Clofazimine is not listed on standard anti-doping panels, but athletes should disclose all medications to their governing body to avoid inadvertent violations.
Both are components of multidrug therapy for leprosy, but clofazimine’s primary benefit is its anti-inflammatory effect and long-acting activity, while dapsone works by inhibiting folate synthesis. They are used together, not as substitutes.
As of the latest regulatory update, clofazimine is marketed in Hong Kong only under the Lamprene brand; generic equivalents may be obtainable in other regions but are not currently approved locally.
Take the missed dose as soon as possible unless the next scheduled dose is within a few hours; in that case, skip the missed dose and continue with the regular schedule-do not double the dose.
The 50 mg strength allows clinicians to titrate the dose according to patient tolerance and to combine two tablets for a 100 mg daily regimen, providing flexibility in dosing.
